8VC’s Investment in Unlearn.AI

Imagine you have an incurable disease — maybe Alzheimer’s or multiple sclerosis. Though you might be willing to take a chance on science, you would nonetheless face a difficult decision in choosing whether to volunteer for a clinical trial. While you could potentially receive a better treatment, it’s equally likely that you would instead receive a placebo as part of the control arm of the study, used to verify the efficacy of the experimental drug. Despite bravely seeking to improve your life, you might end up as just a baseline comparator. That system doesn’t seem right.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

How will AI transform the future of medicine?

White Papers

Evaluating Digital Twins for Alzheimer’s Disease using Data from a Completed Phase 2 Clinical Trial

White Papers

Prognostic digital twins overcome the limitations of external control arms in RCTs

Both methods reduce control arm sizes, but only digital twins control for bias.
A Phase 2 study on crenezumab in mild-to-moderate AD was used to retrospectively assess the validity of Unlearn's approach for AD clinical trials.
Hear from Charles Fisher, founder and CEO of Unlearn, in this on-demand webinar about how AI will transform the medical landscape of tomorrow.